Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

CDC and FDA to monitor recipients of Moderna, Pfizer COVID-19 vaccines for Bell’s Palsy

By Brian Buntz | December 16, 2020

Image by Angelo Esslinger from Pixabay

CDC and FDA have committed to monitoring recipients of two COVID-19 vaccines for Bell’s palsy, a type of facial paralysis.

FDA, however, concluded that there is insufficient data to determine whether the mRNA-based vaccines from Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE)/BioNTech (NSDQ:BNTX) are linked to the condition, which is often temporary. 

Both vaccines use messenger RNA technology, which is novel for vaccines.

In Phase 3 clinical trials from Pfizer-BioNTech and Moderna, a handful of patients developed the condition. Four patients in the vaccine arm of the Pfizer-BioNTech trial developed Bell’s palsy and none in the placebo group. Three patients in the Moderna trial’s vaccine arm developed the condition, and one in the placebo arm.  

“We don’t know really if these Bell’s palsy [cases] ended up happening coincidentally in the vaccine group. We’ll have to see,” said Abinash Virk, an infectious disease specialist at the Mayo Clinic, last week before FDA released its assessment of the Moderna Phase 3 trial. 

A limited number of COVID-19 patients have developed Bell’s palsy as well.

An FDA briefing document for Moderna’s vaccine stated that one case in the vaccine group was a serious adverse event. A “67-year-old female with diabetes was hospitalized for stroke due to new facial paralysis 32 days after vaccination,” according to the report. “This case was reported as resolving,” it continued.  

The Bell’s palsy cases in the Pfizer-BioNTech and Moderna trials will “create some ongoing discussion,” concluded a briefing note from UBS analysts Navin Jacob and Dr. Jonathan Lim. 

But some degree of Bell’s palsy would be expected in a large clinical trial, according to UBS. The background rate of the condition in the general population is 25 to 35 per 100,000 people, which would imply eight to 12 cases across the Pfizer-BioNTech and Moderna trials, which involved approximately 44,000 and 30,000 participants, respectively. There were a total of eight Bell’s palsy cases across both trials. 

While the cause of Bell’s palsy is unclear, reactivation of a dormant viral infection could be the principal cause of the disorder, according to the NIH. Reactivation of herpes simplex virus may be the most common cause. Pregnancy and diabetes can increase the risk of the condition.

Researchers have linked Bell’s palsy to other vaccine studies. In Switzerland, health authorities pulled an inactivated intranasal flu vaccine linked to the condition from the market in the early 2000s. One study conservatively estimated that recipients of that vaccine were 19 times more likely to develop Bell’s palsy than the general population.

FDA researched similar conclusions about the situation in its briefing documents for the Pfizer-BioNTech and Moderna vaccines. “Considering the temporal association and biological plausibility, a potential contribution of the vaccine to the manifestations of these events of facial palsy cannot be ruled out,” the agency concluded in its notes on the Moderna vaccine. The agency is recommending surveillance for Bell’s palsy as both vaccines reach the public. 

FDA authorized the Pfizer-BioNTech vaccine last week. It could authorize the Moderna vaccine as soon as Dec. 18.   

Comments

  1. Kathy says

    January 8, 2021 at 6:08 pm

    My aunt had bell’s palsy. She passed September 30th from leukemia. Is it safe for her nieces and nephews to get the vaccine?

    Reply
    • Brian Buntz says

      January 8, 2021 at 6:28 pm

      Hi Kathy, to date, there is no causal link between the vaccine and Bell’s palsy although FDA and CDC will monitor recipients of the vaccine. FDA said there was “a numerical imbalance” in the clinical trial results. That is, the rates of Bell’s palsy were higher in the vaccinated arms of the Pfizer and Moderna trials. But as things stand now, scientists don’t know if there is a very small risk of Bell’s palsy from the vaccine or if the cases were unrelated to the vaccine. More monitoring should shed light on that question, but in general both the Moderna and Pfizer vaccines have been well-tolerated by most patients.

      Reply
  2. Ken says

    January 10, 2021 at 12:43 pm

    I’m a 73 year old male who has had two previous onsets of Bell’s Palsy in the last 20 years. Both resolved within two weeks with no lingering impact. My last onset was 10 years ago. I can not find any data on onset of Bell’s Palsy with AstraZeneca or J & J vaccines. Has there been any data released ? Has any US cases of Bell’s Palsy been reported since 12/10/20 from the Moderna or Pfizer? Thanks

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson
Johnson & Johnson vaccine trial results expected soon
OncoSec eyes next steps with its cancer immunotherapy candidate
Pharma researcher charged with theft of trade secrets  
Norway investigating deaths of 23 individuals who received COVID-19 vaccine

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards